Psychedelic Weekly Headlines | July 15th

July 15, 2022

Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

Cybin ($CYBN) completed the acquisition of a Phase I DMT study from Entheon Biomedical. The study is expected to accelerate the clinical development path of CYB004, Cybin's proprietary deuterated DMT molecule used as a potential treatment for anxiety disorders. Press Release

Optimi Health (OPTI | $OPTHF) finalized a supply agreement with Bloom Psychedelic Therapy And Research Centre, a mental health service provider, including psychedelic-assisted therapies. Optimi will supply Bloom with natural psilocybin to begin conducting their previously announced clinical trial. Press Release

Filament Health ($FH | $FLHLF) has been issued a third describing essential technology for transforming psychedelic raw materials into pharmaceutical-grade, standardized drug candidates and closed their private placement, raising C$2.5M. Details

PharmaTher Holdings ($PHRM | $PHRRF) has been provided a Notice of Allowance for patent application which includes claims intended to cover ketamine as a potential treatment of Parkinson’s Disease and motor disorders.Press Release

Awakn Life Sciences ($AWKN | $AWKNF) provided operational updates. Highlights included the initiation of their Innovative Licensing and Access Pathway application for their lead program Project Kestrel, filed a Patent Cooperation Treaty for MDMA-assisted therapy for the treatment of AUD and signed a Letter of Intent with Mindcure. Press Release

Nova Mentis Life Science ($NOVA | $NMLSF) presented at the International Fragile X Conference, highlighting recent research results showing significantly modulated behavioural and cognitive defects from a very low microdose formulation of the Company's proprietary psilocybin drug (NM-1001). Press Release


TIME: Doctors Urge Access to Psychedelic Therapies in New Mexico

Wall Street Journal: Investors See Far Out Profits in Psychedelic Medicine

Washington Post: Ann Shulgin, Pioneer Of Psychedelics In Therapy

New York Times: Taking the Magic Out of Psychedelics

Intercept: House Moves To Expand Psychedelic Therapy Research

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.